CY1108054T1 - Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων mu - Google Patents
Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων muInfo
- Publication number
- CY1108054T1 CY1108054T1 CY20071100828T CY071100828T CY1108054T1 CY 1108054 T1 CY1108054 T1 CY 1108054T1 CY 20071100828 T CY20071100828 T CY 20071100828T CY 071100828 T CY071100828 T CY 071100828T CY 1108054 T1 CY1108054 T1 CY 1108054T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapy
- discussion
- competitive
- objectives
- competitive objectives
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000002860 competitive effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000051367 mu Opioid Receptors Human genes 0.000 abstract 2
- 108020001612 μ-opioid receptors Proteins 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- INUCRGMCKDQKNA-CEMLEFRQSA-N cyprodime Chemical compound N1([C@@H]2CC=3C=CC=C(C=3[C@@]3([C@]2(CCC(=O)C3)OC)CC1)OC)CC1CC1 INUCRGMCKDQKNA-CEMLEFRQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Resistance Heating (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815618.5A GB9815618D0 (en) | 1998-07-18 | 1998-07-18 | Treatment of dyskinesia |
| EP99932991A EP1096936B1 (en) | 1998-07-18 | 1999-07-16 | Treatment of dyskinesia through mu selective opioid antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108054T1 true CY1108054T1 (el) | 2013-09-04 |
Family
ID=10835727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100828T CY1108054T1 (el) | 1998-07-18 | 2007-06-21 | Θεραπεια της δυσκινησιας μεσω ανταγωνιστων επιλεκτικων οπιουχων mu |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US6455536B1 (OSRAM) |
| EP (2) | EP1096936B1 (OSRAM) |
| JP (2) | JP2002520362A (OSRAM) |
| AT (1) | ATE357917T1 (OSRAM) |
| AU (1) | AU759342B2 (OSRAM) |
| CA (1) | CA2338066C (OSRAM) |
| CY (1) | CY1108054T1 (OSRAM) |
| DE (1) | DE69935670T2 (OSRAM) |
| DK (1) | DK1096936T3 (OSRAM) |
| ES (1) | ES2285845T3 (OSRAM) |
| GB (1) | GB9815618D0 (OSRAM) |
| PT (1) | PT1096936E (OSRAM) |
| WO (1) | WO2000003715A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
| GB9924941D0 (en) * | 1999-10-22 | 1999-12-22 | Univ Manchester | Treatment of dyskinesia |
| GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2006131545A (ja) * | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
| WO2008133297A1 (ja) | 2007-04-24 | 2008-11-06 | Toray Industries, Inc. | ジスキネジアの治療または予防剤 |
| US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
| US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| JP6406713B2 (ja) | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| EP3436013A4 (en) | 2016-03-31 | 2019-11-13 | Versi Group, LLC | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON |
| CA3166928A1 (en) | 2020-01-10 | 2021-07-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
| US12384197B2 (en) | 2022-07-15 | 2025-08-12 | Swimc Llc | Coating material container |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390699A (en) | 1981-07-16 | 1983-06-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 6-Keto-morphinans belonging to the 14-hydroxy-series |
| US4684620A (en) * | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| ATE110057T1 (de) * | 1987-04-16 | 1994-09-15 | Lilly Co Eli | Piperidine als opioid-antagoniste. |
| ES2148174T3 (es) * | 1991-02-25 | 2000-10-16 | Univ Boston | Antagonista de receptores opiaceos que modula trastornos de movimientos hipercineticos. |
| AU7112094A (en) * | 1993-06-23 | 1995-01-17 | Regents Of The University Of California, The | Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments |
| US5473620A (en) | 1993-09-21 | 1995-12-05 | Cirrus Logic, Inc. | Programmable redundancy/syndrome generator |
| US5464841A (en) * | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
| US5597309A (en) * | 1994-03-28 | 1997-01-28 | Riess; Thomas | Method and apparatus for treatment of gait problems associated with parkinson's disease |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| US5821219A (en) * | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
-
1998
- 1998-07-18 GB GBGB9815618.5A patent/GB9815618D0/en not_active Ceased
-
1999
- 1999-07-16 JP JP2000559850A patent/JP2002520362A/ja active Pending
- 1999-07-16 EP EP99932991A patent/EP1096936B1/en not_active Expired - Lifetime
- 1999-07-16 DK DK99932991T patent/DK1096936T3/da active
- 1999-07-16 US US09/743,965 patent/US6455536B1/en not_active Expired - Lifetime
- 1999-07-16 AT AT99932991T patent/ATE357917T1/de active
- 1999-07-16 WO PCT/GB1999/002146 patent/WO2000003715A1/en not_active Ceased
- 1999-07-16 EP EP07003196A patent/EP1792617A1/en not_active Withdrawn
- 1999-07-16 ES ES99932991T patent/ES2285845T3/es not_active Expired - Lifetime
- 1999-07-16 PT PT99932991T patent/PT1096936E/pt unknown
- 1999-07-16 AU AU49180/99A patent/AU759342B2/en not_active Ceased
- 1999-07-16 CA CA002338066A patent/CA2338066C/en not_active Expired - Fee Related
- 1999-07-16 DE DE69935670T patent/DE69935670T2/de not_active Expired - Lifetime
-
2002
- 2002-05-20 US US10/147,853 patent/US20020137669A1/en not_active Abandoned
- 2002-08-02 US US10/210,061 patent/US6740659B2/en not_active Expired - Lifetime
-
2004
- 2004-04-07 US US10/819,345 patent/US20050009856A1/en not_active Abandoned
-
2007
- 2007-06-21 CY CY20071100828T patent/CY1108054T1/el unknown
-
2009
- 2009-08-31 US US12/585,014 patent/US8198294B2/en not_active Expired - Fee Related
-
2010
- 2010-10-08 JP JP2010228049A patent/JP2011037877A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU4918099A (en) | 2000-02-07 |
| DE69935670T2 (de) | 2008-01-31 |
| CA2338066A1 (en) | 2000-01-27 |
| CA2338066C (en) | 2009-01-27 |
| WO2000003715A1 (en) | 2000-01-27 |
| ATE357917T1 (de) | 2007-04-15 |
| DK1096936T3 (da) | 2007-07-30 |
| DE69935670D1 (de) | 2007-05-10 |
| JP2002520362A (ja) | 2002-07-09 |
| EP1096936B1 (en) | 2007-03-28 |
| EP1792617A1 (en) | 2007-06-06 |
| US8198294B2 (en) | 2012-06-12 |
| GB9815618D0 (en) | 1998-09-16 |
| JP2011037877A (ja) | 2011-02-24 |
| US20100184797A1 (en) | 2010-07-22 |
| US6740659B2 (en) | 2004-05-25 |
| US20020137669A1 (en) | 2002-09-26 |
| EP1096936A1 (en) | 2001-05-09 |
| US20050009856A1 (en) | 2005-01-13 |
| US6455536B1 (en) | 2002-09-24 |
| AU759342B2 (en) | 2003-04-10 |
| US20030060478A1 (en) | 2003-03-27 |
| ES2285845T3 (es) | 2007-11-16 |
| PT1096936E (pt) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108539T1 (el) | Ανταγωνιστες υποδοχεα ταχυκινινης | |
| DE60222396D1 (de) | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste | |
| EA200101177A1 (ru) | Производные индола в качестве антагонистов прогестерона | |
| IL161074A0 (en) | Lactam derivatives as antagonists for human 11cby receptors | |
| NO983431D0 (no) | Anti-kl°emidler | |
| DK1263752T3 (da) | LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf | |
| DK1096936T3 (da) | Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister | |
| MX9300842A (es) | Antagonistas de endotelina de sulfonamida. | |
| CY1106781T1 (el) | Περιορισμενα ως προς τη διαμορφωση κυκλοποιημενα στην κυρια αλυσιδα αναλογα σωματοστατινης | |
| CY1109061T1 (el) | Αναλογα ομοιου με γλυκαγονη πεπτιδιου-1 | |
| ES2184797T3 (es) | Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia. | |
| BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
| NO994850L (no) | Farmakologiske midler | |
| NO20020574D0 (no) | Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden | |
| TR200000792T2 (tr) | Vitronektin reseptör antagonistleri. | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| PT1171419E (pt) | Derivados de bifenilo como antagonistas do receptor da neuroquinina-1 | |
| TR200101654T2 (tr) | Vitronektin reseptr antagonistleri | |
| SE9702794D0 (sv) | New compounds | |
| ES2156889T3 (es) | Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos. | |
| ES2172939T3 (es) | Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores. | |
| MX9307047A (es) | Compuestos de quinazolinas y bencimidazoles substituidos. | |
| ES2189940T3 (es) | Antagonista de receptor at1 para la estimulacion de la apoptosis. | |
| CY1106194T1 (el) | Θepαπευτικη αγωγη της δυσκινησιας | |
| CY1115760T1 (el) | Τικαγρελορη για την θεραπευτικη αγωγη ανευρυσματων κοιλιακης αορτης |